Cline Scientific AB Series B
Cline Scientific AB (publ), a life science company, develops cancer diagnostics and stem cell therapies in Sweden. The company's clinical-stage projects include StemCART, a stem cell therapy for joint repair; and CellRACE, a cancer diagnostic to predict metastasis. It also develops nanotechnology based products for work within Life Sciences. The company has collaboration with Sahlgrenska that dev… Read more
Market Cap & Net Worth: Cline Scientific AB Series B (CLINE-B)
Cline Scientific AB Series B (ST:CLINE-B) has a market capitalization of $256.80K (Skr2.88 Million) as of March 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #39584 globally and #644 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cline Scientific AB Series B's stock price Skr0.07 by its total outstanding shares 41751800 (41.75 Million).
Cline Scientific AB Series B Market Cap History: 2015 to 2025
Cline Scientific AB Series B's market capitalization history from 2015 to 2025. Data shows change from $50.24 Million to $256.80K (-44.20% CAGR).
Cline Scientific AB Series B Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cline Scientific AB Series B's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.23x
Cline Scientific AB Series B's market cap is 0.23 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $50.24 Million | $409.47K | -$2.27 Million | 122.71x | N/A |
| 2016 | $35.73 Million | $911.85K | -$2.83 Million | 39.18x | N/A |
| 2017 | $22.89 Million | $457.23K | -$3.33 Million | 50.06x | N/A |
| 2018 | $13.40 Million | $820.25K | -$2.51 Million | 16.33x | N/A |
| 2019 | $9.60 Million | $282.82K | -$2.41 Million | 33.95x | N/A |
| 2020 | $10.79 Million | $116.58K | -$2.03 Million | 92.58x | N/A |
| 2021 | $8.75 Million | $3.99K | -$3.57 Million | 2191.49x | N/A |
| 2022 | $3.60 Million | $2.90 Million | -$2.35 Million | 1.24x | N/A |
| 2023 | $967.67K | $4.20 Million | -$3.15 Million | 0.23x | N/A |
Competitor Companies of CLINE-B by Market Capitalization
Companies near Cline Scientific AB Series B in the global market cap rankings as of March 19, 2026.
Key companies related to Cline Scientific AB Series B by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Cline Scientific AB Series B Historical Marketcap From 2015 to 2025
Between 2015 and today, Cline Scientific AB Series B's market cap moved from $50.24 Million to $ 256.80K, with a yearly change of -44.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | Skr256.80K | 0.00% |
| 2024 | Skr256.80K | -73.46% |
| 2023 | Skr967.67K | -73.11% |
| 2022 | Skr3.60 Million | -58.85% |
| 2021 | Skr8.75 Million | -18.97% |
| 2020 | Skr10.79 Million | +12.40% |
| 2019 | Skr9.60 Million | -28.33% |
| 2018 | Skr13.40 Million | -41.46% |
| 2017 | Skr22.89 Million | -35.94% |
| 2016 | Skr35.73 Million | -28.89% |
| 2015 | Skr50.24 Million | -- |
End of Day Market Cap According to Different Sources
On Jan 30th, 2026 the market cap of Cline Scientific AB Series B was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $256.80K USD |
| MoneyControl | $256.80K USD |
| MarketWatch | $256.80K USD |
| marketcap.company | $256.80K USD |
| Reuters | $256.80K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.